Clinical Trial Update: EGO-COMBO Clinical End-point Extension Study Beyond 36 Months

View source ↗

Summary

Clinical trial update indicates the EGO-COMBO endpoint extension study for coronary restenosis has extended beyond 36 months and is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Restenosis

Snippet

Sponsor: The University of Hong Kong | Conditions: Coronary Restenosis | Status: COMPLETED